Treatment-resistant non-catatonic mutism in schizophrenia: A case report and review of literature

Grover, Sandeep; Naskar, Chandrima; Sharma, Payal

doi:10.1016/j.ajp.2022.103067

Cited by 4 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as an extreme form of alogia). Mutism might develop in a patient, even involuntarily, to mitigate the distress caused by paranoid delusions or hallucinations or to disguise the illness and reduce the associated stigma [125]. A recent report suggests that religion and the psychological uses of silence appear to play a part in the occurrence of the symptom of mutism [126].…”

Section: Psychomotor Disturbancesmentioning

confidence: 99%

New Directions for Symptoms and Diagnosis in Schizophrenia

Crecan-Suciu¹,

Paunescu²

2023

Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives

View full text Add to dashboard Cite

Schizophrenia represents one challenging mental disorder from all the psychotic spectrum, considered to be a major health problem worldwide and because of the characteristic symptoms, the diagnosis is associated with high levels of stigmatization. It is quite common that the first acute symptoms to occur in early adult life and cause severe distress not only to the patient in need but also to their families. The schizophrenia clinical picture is usually misunderstood by the general public and consists of positive symptoms, negative symptoms, disorganized speech or behavior during a specific amount of time. In order to establish an accurate diagnosis, it requires taking into consideration both international classification systems, Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and The International Classification of diseases (ICD-10), adding a fresh perspective to the newest chapter of ICD-11 called “Schizophrenia or other primary psychotic disorders”, alongside with the diagnosis criteria, other new symptoms such as cognitive impairment emerge as an important feature of schizophrenia.

show abstract

Section: Psychomotor Disturbancesmentioning

confidence: 99%

New Directions for Symptoms and Diagnosis in Schizophrenia

Crecan-Suciu¹,

Paunescu²

2023

Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives

View full text Add to dashboard Cite

show abstract

“…In the vast majority of circumstances, they outperform standard machine learning algorithms. Many researchers have utilized DL in the field of EEG to investigate mental health to diagnose and classify diseases [123][124][125][126]. [36] and SZ [127].…”

Section: In-silico Applications In Schizophrenia and Future Perspectivesmentioning

confidence: 99%

Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives

2023

View full text Add to dashboard Cite

specializing in neuropharmacology. She has worked at Eli Lilly and Company, Indianapolis, USA and has a clinical practice that offers brain mapping and applied behavior analysis (ABA), Indiana Brain Mapping. Her research is on the brain circuit that underlies neurological disorders including depression, autism, and schizophrenia. Although trained in drug development, she has pioneered cutting-edge applications to the treatment of mental disorders from both neurobiology and behavioral science and uses natural environment modification as a treatment approach. She pioneered the use of portable brain imaging to guide behavior treatment for various mental disorders, including schizophrenia. As a member of ABAI and an NGO member of the United Nations, she works on outreach projects in Asia to advance the Universal Declaration of Human Rights, aiming to promote better recognition of individuals with mental disabilities, including schizophrenia. Her overarching aim to is advance treatment intervention, and apply innovative brain-mapping technology to help the public understand mental disorders.

show abstract

“…The increase in the number of therapeutically resistant patients with paranoid schizophrenia with auto aggression remains one of the most pressing problems in psychiatry remains as the most common nosological unit [1,2,3]. At the same time, a large amount of research material has been accumulated on the factors and conditions that affect the formation of the state of resistance in such patients [4,5,6,7]. First of all, these include: a debut at an early age, an "erased" beginning, a continuous course, the dominance of negative symptoms in the structure of the pathological process, and the fading of the affective component.…”

mentioning

confidence: 99%

Comparative Analysis of Combination Therapy Regimens in Patients with Paranoid Schizophrenia with Non-Suicidal Auto aggression and Identified Signs of Resistance to Ongoing Neuroleptic Monotherapy

I.V.

2023

JNNS

View full text Add to dashboard Cite

A comparative analysis of combination therapy regimens was carried out in patients with paranoid schizophrenia with NSAA and identified signs of resistance to ongoing neuroleptic monotherapy. In total, in the period from 2015 to 2022, 155 patients with paranoid schizophrenia with NSAA were studied as part of a multicenter randomized longitudinal study. It has been established that the first-line therapy regimen in this group of patients is a combined regimen of clozapine with haloperidol.Introduction. The increase in the number of therapeutically resistant patients with paranoid schizophrenia with auto aggression remains one of the most pressing problems in psychiatry remains as the most common nosological unit [1,2,3]. At the same time, a large amount of research material has been accumulated on the factors and conditions that affect the formation of the state of resistance in such patients [4,5,6,7]. First of all, these include: a debut at an early age, an "erased" beginning, a continuous course, the dominance of negative symptoms in the structure of the pathological process, and the fading of the affective component. A special place among the clinical predictors of therapeutic resistance is occupied by psychopathic disorders with auto aggressive tendencies, traditionally considered within the framework of heboid states. At the same time, until recently, the main drug from the group of neuroleptics used to overcome resistance was clozapine [8,9,10,11,12,13]. In practice, up to 30% of patients remain intact to its action, which dictates the need for combination therapy [14,15,16]. This predetermines the search for new schemes for the use of medicinal drugs to solve this problem.

show abstract

Treatment-resistant non-catatonic mutism in schizophrenia: A case report and review of literature

Cited by 4 publications

References 11 publications

New Directions for Symptoms and Diagnosis in Schizophrenia

New Directions for Symptoms and Diagnosis in Schizophrenia

Schizophrenia - Recent Advances and Patient-Centered Treatment Perspectives

Comparative Analysis of Combination Therapy Regimens in Patients with Paranoid Schizophrenia with Non-Suicidal Auto aggression and Identified Signs of Resistance to Ongoing Neuroleptic Monotherapy

Contact Info

Product

Resources

About